Giving what was once considered little more than a psychedelic “party drug” to people suffering from post-traumatic stress disorder (PTSD) can dramatically increase the effectiveness of therapy, a new study suggests. Researchers from the University of California made the claim Tuesday at a virtual symposium after conducting a Phase 3 medical trial involving 90 participants. For the trial, researchers gave the participants 120mg of MDMA — commonly known as “molly” or “ecstasy” — before they underwent an eight-hour PTSD therapy session. That process was repeated three times over the course of two months.
Load More
Load More